The US Department of Justice’s (DOJ) revised compliance program document “The Evaluation of Corporate Compliance Programs,” released June 1, 2020, helps organizations understand how DOJ evaluates compliance programs for effectiveness. Below are the the top takeaways from this revision that
Health & Life Sciences News
Exploring Critical Business and Legal Issues across the Health Care and Life Sciences Industries
Health & Life Sciences News, published by McDermott Will & Emery, focuses on legal and regulatory developments affecting the healthcare and life sciences sectors. The blog covers topics such as healthcare mergers and acquisitions, compliance programs, antitrust considerations, provider collaborations, and the impact of public health emergencies like COVID-19 on healthcare operations and life sciences companies. It also addresses FDA regulatory issues, clinical trial innovations, supply chain challenges, and government assistance programs relevant to healthcare and life sciences businesses. The content includes analysis of transactional, compliance, and policy matters shaping the industry landscape.
Blog Authors
Latest from Health & Life Sciences News
Unpacking Differences in Public and Private Hospital M&A
Across the public hospital sector, M&A activity has increased significantly over the past decade. Given the current COVID-19 landscape, many are taking a hard look at their operations to garner a better understanding of what needs to be done to…
Top Takeaways: Permissible Provider Collaborations During COVID-19 and Beyond
As the healthcare industry continues to cope with the Coronavirus (COVID-19) and form strategic and short- and long-term plans, providers are faced with numerous decisions that have critical antitrust implications. Whether seeking to collaborate with competitors for pandemic response or…
More Than a Decade at the Top; McDermott Earns 11th Chambers USA Band 1 Healthcare Practice National Ranking
We are pleased to announce that our Healthcare Group received a national Band 1 ranking for the eleventh year in a row in the 2020 edition of Chambers USA. After more than a decade at the top, we are once…
Top Takeaways: Critical Business Considerations for Life Sciences and Medical Device Companies During COVID-19
Life sciences and medical device companies are dealing with an unprecedented crisis. The industry is not only managing the impact of Coronavirus (COVID-19), they are also a solution provider. Companies are rapidly adapting products, services, facilities and distribution channels to…
Coronavirus Resource Center | Preparedness Planning for Businesses
In our global economy, Coronavirus (COVID-19) raises serious concerns for employers in all industries. Workers may be on the front lines caring for patients and developing vaccines, travelling for business, or in close contact with individuals who travel or may…
Five Questions with a Health Lawyer: Nicholas Alarif
Nicholas Alarif
Office: Washington, DC
Years at Firm: 3
What is your favorite part about practicing healthcare law at McDermott?
I hate to sound like a broken record, but the best part about practicing at McDermott is the innovative and…
Five Questions with a Health Lawyer: Matt Perreault
Matt Perreault
Office: Boston
Years at Firm: 2
What is your favorite part about practicing health care law at McDermott?
As so many of my colleagues have expressed throughout this series, my favorite part of practicing healthcare law at…
2019 Hospital and Health Systems Year in Review
Hospitals and health systems are facing consumer demand for innovation, the need to expand and enhance streams of revenue and the push for improved quality, all while navigating changing regulations, federal enforcement, antitrust litigation and business pressures. 2019 saw hospitals…
Anticompetitive Conduct in Biologics – An Enforcement Priority with FTC and FDA
This blog was originally published on McDermott’s Antitrust Alert Blog.
On February 4, 2020, the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) released joint guidance concerning competition for biologics, including biosimilars. The joint guidance seeks…